GRIFOLS SA INH. A EO-,25/ ES0171996087 /
| 7/29/2024 10:58:56 PM | Chg. -0.080 | Volume | Bid10:58:56 PM | Ask10:58:56 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 9.006EUR | -0.88% | - Turnover: - |
9.006Bid Size: - | 9.154Ask Size: - | 7.71 bill.EUR | - | 101.04 |
GlobeNewswire
7/1
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
GlobeNewswire
6/18
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
GlobeNewswire
6/17
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immu...
GlobeNewswire
4/18
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at ...
GlobeNewswire
4/4
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Scree...
GlobeNewswire
11/15/2023
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous ...
